Transcript Critical Issues

Monday Pre-Meeting
• About ½ of this seminar’s participants met this
afternoon in what turned out to b and ad-hoc,
informal brainstorming session
• Key outcome: we need to come out of these
three days with a 1-2 campaigns with
global/regional and national components; some
way to coordinate this work and; support and
finance it
• Two main campaign suggestions: on FTAs and
Global Fund
• There is a plan by MSF to hold an A2M strategy
meeting in January/February with a larger group;
this must be a follow-up to our meeting this week
Action Items: Short Term and Long
Term
• Short Term
– Free Trade Agreements
– Barriers to further scale up
of treatment
– Collapse of key institutions
in global response to AIDS
and other diseases
– Need to widen scope of
A2M movement and
partners
• Long Term
– Need for reforms in TRIPS
agreement
– Need a new global
framework on right to
health integrating IP
– Need to address
consolidation in
pharmaceutical industry
– Need to address models of
innovation and ownership
of knowledge
– Need to address
technology transfer issues
in drug and diagnostics
manufacture
Critical Short Term Issues
• Collapse of Health Institutions
• Free Trade Agreements
–
–
–
–
–
USA/Asia-Pacific
EU/Asia
EU/Africa
EU/Mercosur
ACTA (counterfeit)
– Global Fund cancellation of
Round 11—need for US$2B in
200 days
– Need for major reforms within
Global Fund
• Re-focus activities on
A2M/treatment
• Address overhead/waste
• Explore re-programming of
existing funds
– Need to address centralized,
privatized procurement of
drugs (e.g. Clinton, UNITAID,
PEPFAR)
– Need to address effect of
Global Fund set-backs on
marginalized populations at
national level
• WHO privatization (esp.
Essential Drugs Department)
Critical Short Term Issues
• Widening the Movement
– Need to address NCDs
• Targets and commitments by
WHO
– Need to address HCV/HBV/TB
– Need to engage broader
health movements
– Need to engage other
partners key to work on FTAs
etc. (e.g. food security
groups, Swedish Pirate Party,
Occupy Wall St.)
– Need to develop grassroots
approach to IP/trade/access
literacy
– Need to outreach to trade
ministries
• Scale Up of Treatment
– Encourage LDCS to extend
deadline beyond 2016
– Reach out systematically to
generic and API producers
(esp. in China, Eastern
Europe, etc)
– Streamline drug prequalification and other
quality assessment
mechanisms
– Bring back a discussion of
industrial policy to foster local
generic production
– Quietly support Chinese CL on
TDF
– Ensure greater, independent
oversight of treatment
guideliens development
Potential Campaign Strategies: FTAs
•
•
•
•
•
•
•
•
•
Lobbying US Congress and White House
Demonstrations at US/EU embassies and consulates
Demonstration at International AIDS Conference
Targeting current negotiations happening from
January-March (e.g. Australia)
Developing alternative text for trade agreements
Outreach to trade ministers
Developing new “sexy” media strategy
Developing new social media strategy
Missing the Target Report on IP Barriers to ART Access